Quay Pharma is now part of sgs logoopens in a new window


Company Overview


We are committed to finding the best formulation and dosage delivery solution for every product.

Within Quay Pharma we can provide virtually all of the services required to bring drug products through the various stages of development quickly and cost-effectively.

At Quay Pharma, we are committed to finding the best formation and dosage delivery solution for every product, whether it is a New Chemical Entity (NCE), classic drug substance or a live biotherapeutic, to give it the best possible chances of clinical and commercial success.

We have an extensive portfolio of pharmaceutical technologies that allow us to develop formulations that present particular challenges.

Complementing our more traditional drug products, these allow us to develop novel medications that will be effective in key therapeutic areas, as well as introducing significant performance advantages over existing products. Our technologies include:

  • Conventional dosage forms.
  • Drug solubilisation and bioavailability enhancement.
  • Controlled release and gastrointestinal targeting.
  • Live Biotherapeutics.
Modified Release Technology

There are many possible reasons why a drug may require modified or targeted release. Some of these are related to the characteristics of the product itself, such as its pharmacodynamic or pharmacokinetic profile and the need to avoid degradation in specific areas of the gastrointestinal tract, or a desire to manage a product’s life cycle in the market. Others arise from clinical considerations like the importance of taking a drug to the precise site in the gut where the release will be most effective or improving patient compliance.

At Quay Pharma, we have world-leading expertise in the science of modified release technologies, and a wealth of experience covering a wide range of modified and targeted release projects. We can provide you with a vast range of options to modify the rate at which an API is released, and for ensuring that it is delivered only to a specific, predetermined site within the gastrointestinal tract. All of the formulations we develop are provided to clients with full Intellectual Property rights, and on a royalty-free basis.

Drug Coating Technologies

Enhance systemic delivery by directing the release of the API to specific areas of the small intestine or colon.

Find Out More

Modified Release Microparticles

Microparticles are suitable for a broad range of drug delivery applications, and they offer many advantages.

Find Out More

Multiparticulate Drug Delivery

Beads, pellets, granules or mini-tablets offer enormous flexibility in their drug release profiles.

Find Out More

Modified Release Tablets

Coated and uncoated modified release tablets in a wide range of shapes, sizes, finishes and release profiles.

Find Out More
Solubility & Bioavailability

Solubility and bioavailability are overwhelming challenges in drug development. We have a range of practical, proven approaches for overcoming these barriers. Approximately 40% of all drugs currently on the market, and 90% of the compounds at present in development for future use, are reported to show poor solubility in water. This leads to difficulties in obtaining adequate, reproducible absorption from the gastrointestinal tract after oral administration. Poor solubility and variable drug absorption are associated with low bioavailability, and ultimately affect the efficacy and safety of the product.

Class 1 (High Solubility) High Solubility, High Permeability, Rapid Dissolution. Class 1 drugs do not normally exhibit bioavailability problems. However, from a pharmacokinetic perspective, a slower but longer-lasting release would sometimes be preferable.

Class 2 (Low Solubility) Low Solubility, High Permeability. Class 2 includes the majority of NCEs in the development pipelines. Their solubility in the gastrointestinal tract has to be increased to allow them to be formulated into marketable products

Class 3 (High Solubility) High Solubility, Low Permeability. Class 3 drugs are soluble in the gastrointestinal tract but not readily taken up by the body. Permeation enhancing techniques are required to to turn them into clinically effective products

Class 4 (Low Solubility) High Solubility, Low Permeability. Class 4 contains substances that neither dissolve nor penetrate physiological barriers to enter the body. They are not usually developed further, although they may have some application when used with pro-drugs.

Our unparalleled range of technologies designed to increase the solubility or permeability of drug compounds have applications throughout the development process, from the earliest stages to commercialisation. Provided on a royalty-free basis, they include:

pH Control

Adjustment of the pH value for increasing the water solubility of ionisable compounds.

Find Out More

Particle Size Reduction

Where drugs exhibit reduced bioavailability due to poor solubility, the cause is often intrinsically linked with particle size.

Find Out More

Solid Dispersions

Solid dispersions work by dispersing the poorly-soluble drug within a highly soluble solid hydrophilic matrix.

Find Out More

Lipophilic Systems

Highly experienced in identifying the most suitable lipid excipients for the challenges of dispersion, dissolution or digestion

Find Out More
Other Solubilisation Technologies

While lipophilic systems, solid dispersions, particle size reduction and pH control are the principal techniques used to overcome solubility difficulties, we have a wide range of other approaches, such as the ones below, which we use where they will offer results that more closely meet the needs of our clients.

Other Solubilisation

We have a wide range of other solubilisation approaches.

Find Out More

Let's Talk Project Success

Talk directly to the Quay staff - Our dedicated team leaders are ready to listen and help with your project.

Contact Us